ArticleCureus2026
Severe Fetal Anaemia Secondary to Fetomaternal Haemorrhage: A Case Report Exploring Aetiologies and Diagnostics.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clinically significant fetomaternal haemorrhage (FMH) is a rare but significant cause of fetal anaemia, often associated with placental or umbilical cord abnormalities and with obstetric manoeuvres and traumatic events. This case follows a 40-year-old woman in her second pregnancy who sustained a severe, unprovoked FMH resulting in an emergency caesarean section at 34+3 weeks' gestation. While her newborn required cardiopulmonary resuscitation and birth and subsequent respiratory support (including an admission to the neonatal intensive care unit), there was a good recovery. This patient's case is of interest due to the lack of major risk factors (including a reassuring fetal growth and well-being scan just two days prior) and raises questions about screening, risk stratification and effective diagnosis. These can assist in identifying women at the highest risk of developing FMH and facilitate rapid diagnosis in order to minimise maternal and neonatal morbidity and mortality.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.